儿童死亡率中的遗传因素。
The genetic component in child mortality.
作者信息
Roberts D F, Chavez J, Court S D
出版信息
Arch Dis Child. 1970 Feb;45(239):33-8. doi: 10.1136/adc.45.239.33.
Abstract
Analysis of the causes of death in 1041 children in all Newcastle hospitals admitting children in the period 1960 to 1966 shows that genetically determined disease makes a major contribution, 42% in this series, to the total of mortality in childhood. The findings are very similar to a previous survey made in London.
摘要
对1960年至1966年期间纽卡斯尔所有收治儿童的医院里1041名儿童的死因分析表明，遗传决定的疾病在儿童总死亡率中占主要部分，在本系列研究中占42%。这些发现与之前在伦敦进行的一项调查非常相似。
相似文献
1
The genetic component in child mortality.儿童死亡率中的遗传因素。
Arch Dis Child. 1970 Feb;45(239):33-8. doi: 10.1136/adc.45.239.33.
2
Disabilities of genetic origin.
Arch Phys Med Rehabil. 1970 May;51(5):291-6 passim.
3
Medical genetics: an overview.医学遗传学：概述
Pediatr Clin North Am. 1978 Aug;25(3):395-409. doi: 10.1016/s0031-3955(16)33596-9.
4
Genetic disease and childhood mortality.遗传疾病与儿童死亡率。
Arztl Jugendkd. 1990;81(5):313-8.
5
The fate of gene mutations and their impact on human sex ratio.
Acta Psychiatr Scand. 1973;49(3):281-93. doi: 10.1111/j.1600-0447.1973.tb04422.x.
6
Genetic counselling--or what can we tell parents?
Practitioner. 1974 Nov;213(1277):641-6.
7
Chromosomal abnormalities and congenital heart disease.染色体异常与先天性心脏病。
Guys Hosp Rep. 1968;117(4):323-37.
8
[MONGOL CHILD-MOSAIC PARENT. STUDY OF 2 FAMILIES].[蒙古儿童-嵌合型父母。两个家族的研究]
J Genet Hum. 1964 Dec;13:315-36.
9
[Molecular advances in "non-mendelian" genetics. Implications for pediatrics].["非孟德尔式”遗传学的分子进展。对儿科学的影响]
An Esp Pediatr. 1993 Jun;38(6):479-87.
10
Chromosome studies in investigation of stillbirths and neonatal deaths.死产和新生儿死亡调查中的染色体研究。
Arch Dis Child. 1974 Oct;49(10):782-8. doi: 10.1136/adc.49.10.782.
引用本文的文献
1
Triumphs, Trials, and Future Considerations in Genetic Therapies for Hereditary Neuromuscular Diseases.遗传性神经肌肉疾病基因治疗的成就、试验及未来考量
Mo Med. 2025 Jan-Feb;122(1):46-52.
2
Gene replacement therapy for spinal muscular atrophy: safety and preliminary efficacy in a Brazilian cohort.脊髓性肌萎缩症的基因替代疗法：巴西队列中的安全性和初步疗效
Gene Ther. 2024 Jul;31(7-8):391-399. doi: 10.1038/s41434-024-00456-y. Epub 2024 Jun 5.
3
Bridging the gap: R-loop mediated genomic instability and its implications in neurological diseases.弥合差距：R环介导的基因组不稳定性及其在神经疾病中的意义
Epigenomics. 2024 Mar 26;16(8):589-608. doi: 10.2217/epi-2023-0379.
4
Base editing rescue of spinal muscular atrophy in cells and in mice.碱基编辑技术挽救细胞和小鼠中的脊髓性肌肉萎缩症。
Science. 2023 Apr 21;380(6642):eadg6518. doi: 10.1126/science.adg6518. Epub 2023 Apr 14.
5
Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue.onasemnogene abeparvovec DNA、mRNA 和 SMN 蛋白在人体组织中的分布。
Nat Med. 2021 Oct;27(10):1701-1711. doi: 10.1038/s41591-021-01483-7. Epub 2021 Oct 4.
6
Drug Discovery of Spinal Muscular Atrophy (SMA) from the Computational Perspective: A Comprehensive Review.从计算角度看脊髓性肌萎缩症（SMA）的药物发现：全面综述。
Int J Mol Sci. 2021 Aug 20;22(16):8962. doi: 10.3390/ijms22168962.
7
What Genetics Has Told Us and How It Can Inform Future Experiments for Spinal Muscular Atrophy, a Perspective.遗传学告诉了我们什么，以及它如何为未来的脊髓性肌萎缩症实验提供信息：一个视角。
Int J Mol Sci. 2021 Aug 6;22(16):8494. doi: 10.3390/ijms22168494.
8
Awareness screening and referral patterns among pediatricians in the United States related to early clinical features of spinal muscular atrophy (SMA).美国儿科医生在脊髓性肌萎缩症（SMA）早期临床特征方面的意识筛查和转诊模式。
BMC Pediatr. 2021 May 17;21(1):236. doi: 10.1186/s12887-021-02692-2.
9
Intragenic complementation of amino and carboxy terminal SMN missense mutations can rescue Smn null mice.基因内氨基和羧基末端 SMN 错义突变的互补可以拯救 Smn 缺失小鼠。
Hum Mol Genet. 2020 Nov 1;29(21):3493-3503. doi: 10.1093/hmg/ddaa235.
10
Current and emerging treatment options for spinal muscular atrophy.脊髓性肌萎缩症的现有及新出现的治疗选择
Degener Neurol Neuromuscul Dis. 2015 Jul 17;5:75-81. doi: 10.2147/DNND.S48420. eCollection 2015.
Zotero 插件